| 证券代码：688076 | 证券简称：诺泰生物 | 公告编号：2025-025 | | --- | --- | --- | | 转债代码：118046 | 转债简称：诺泰转债 | | 江苏诺泰澳赛诺生物制药股份有限公司 关于实施"诺泰转债"赎回暨摘牌的 第二次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 赎回登记日：2025 年 4 月 24 日 赎回价格：100.1436 元/张 赎回款发放日：2025 年 4 月 25 日 最后交易日：2025 年 4 月 21 日 截至 2025 年 4 月 18 日收市后，距离 4 月 21 日（"诺泰转债"最后交易 日）仅剩 1 个交易日，4 月 21 日为"诺泰转债"最后一个交易日。 最后转股日：2025 年 4 月 24 日 截至 2025 年 4 月 18 日收市后，距离 4 月 24 日（"诺泰转债"最后转股 日）仅剩 4 个交易日，4 月 24 日为"诺泰转债"最后一个转股日。 本次提前赎回完成后，"诺泰转债"将自 2025 年 4 月 2 ...

| 证券代码：688076 | 证券简称：诺泰生物 | 公告编号：2025-024 | | --- | --- | --- | | 转债代码：118046 | 转债简称：诺泰转债 | | 第一次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 赎回登记日：2025 年 4 月 24 日 赎回价格：100.1436 元/张 赎回款发放日：2025 年 4 月 25 日 最后交易日：2025 年 4 月 21 日 截至 2025 年 4 月 17 日收市后，距离 4 月 21 日（"诺泰转债"最后交易 日）仅剩 2 个交易日，4 月 21 日为"诺泰转债"最后一个交易日。 最后转股日：2025 年 4 月 24 日 截至 2025 年 4 月 17 日收市后，距离 4 月 24 日（"诺泰转债"最后转股 日）仅剩 5 个交易日，4 月 24 日为"诺泰转债"最后一个转股日。 本次提前赎回完成后，"诺泰转债"将自 2025 年 4 月 25 日起在上海证 券交易所摘牌。 投资者所持可转债除在规定时限内通过二 ...

| 证券代码：688076 | 证券简称：诺泰生物 | 公告编号：2025-023 | | --- | --- | --- | | 转债代码：118046 | 转债简称：诺泰转债 | | 江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露英克司兰原料药取得 FDA DMF 备案号 的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）控股子 公司杭州诺泰诺和生物医药科技有限公司（以下简称"诺泰诺和"）收到美国食 品药品监督管理局（以下简称"FDA"）关于英克司兰（Inclisiran）原料药的 DMF 回执，公司英克司兰原料药顺利取得 DMF 备案号。现将相关情况公告如下： 一、DMF 备案的相关信息 （一）原料药名称：英克司兰（Inclisiran） 本次英克司兰原料药获得 DMF 备案号后，仍需 FDA 审评方可完成备案，审评 结果尚存在不确定性。由于国际药品注册审批会受到海外市场政策环境变化影响， 公司严格遵守国内外市场药品研发、生产和销售的相关规定，确保药品 ...

| 证券代码：688076 | 证券简称：诺泰生物 公告编号：2025-022 | | --- | --- | | 转债代码：118046 | 转债简称：诺泰转债 | 江苏诺泰澳赛诺生物制药股份有限公司 关于实施"诺泰转债"赎回暨摘牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因实施江苏诺泰澳赛诺生物制药股份有限公司可转换公司债券（以下简称"诺泰转 债"）赎回,本公司的相关证券停复牌情况如下： | 证券代 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌终止 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 码 118046 | 诺泰转债 | 可转债债券停 牌 | 2025/4/22 | 期间 | 日 | | 赎回登记日：2025 年 4 月 24 日 赎回价格：100.1436 元/张 赎回款发放日：2025 年 4 月 25 日 最后交易日：2025 年 4 月 21 日 截至 2025 年 4 月 ...

Core Insights - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. (Nuotai Biopharma) has officially entered into a strategic partnership with Gulf Pharmaceutical Industries (Julphar) to supply semaglutide active pharmaceutical ingredients (APIs) across 22 countries in the Middle East and Africa [2][3] - This collaboration allows Nuotai Biopharma to leverage Julphar's strong commercialization capabilities in the region, enhancing its market presence and international influence in the GLP-1 sector [3][4] Company Overview - Nuotai Biopharma is a significant player in the domestic biopharmaceutical sector, particularly in the GLP-1 field, with modern production facilities in Lianyungang and Jiande [3] - The company has a peptide production capacity of 5 tons per year, with plans to double this capacity by mid-2025 [3] Financial Performance - Nuotai Biopharma anticipates a net profit of 130 million to 170 million yuan for Q1 2025, representing a year-on-year growth of 96% to 156%, primarily driven by increased sales of peptide APIs [3] Market Potential - The Middle East biopharmaceutical market is projected to grow significantly, with an expected market size of $32.615 billion by 2029 and a compound annual growth rate (CAGR) of approximately 8.97% from 2024 to 2029 [4][5] - The partnership is expected to enhance Julphar's product pipeline and competitiveness in the diabetes treatment market in the region [4] Strategic Implications - The collaboration exemplifies a shift in the role of Chinese pharmaceutical companies from mere manufacturers to innovative enterprises with independent intellectual property rights capable of participating in international competition [5] - This partnership is anticipated to set a precedent for future collaborations between Chinese and international pharmaceutical companies, fostering advancements in technology, product development, and market expansion [5]

Group 1 - The first quarterly report for 2025 from the Sci-Tech Innovation Board was released by Xigao Institute, marking it as the first company to disclose such results [2] - Xigao Institute reported a revenue of 207 million yuan for Q1 2025, representing a year-on-year growth of 12.1%, and a net profit of 62.97 million yuan, also up by 12.1% [2] - The overall performance of Sci-Tech Innovation Board companies in Q1 2025 shows positive signals, with 14 companies reporting earnings forecasts, including 9 with expected profit increases and 5 turning losses into profits [2] Group 2 - Linweina, the first chip testing probe company in the A-share market, achieved a revenue increase of 112% in Q1 and turned a profit due to higher sales of high-margin products and expanded sales scale [3] - Tailin Micro, a leader in low-power Bluetooth chips, reported a revenue of 230 million yuan in Q1, with a year-on-year increase of 43% and a net profit increase of approximately 894% [3] - Guanda Special Materials achieved a revenue of 1.12 billion yuan in Q1, with a net profit increase of 1504.79%, driven by strong demand in downstream industries and the effectiveness of its fundraising projects [3][4] Group 3 - Companies like United Imaging and Guoxin Technology are maintaining strong R&D momentum and practical business strategies, with United Imaging reporting over 140 product approvals globally [5] - Guoxin Technology disclosed significant progress in RISC-V architecture development, showcasing its R&D capabilities with successful internal testing of a new high-performance cloud security chip [5] - Zhongchuan Special Gas reported a 142.42% year-on-year increase in new orders for its trifluoromethanesulfonic acid series products in Q1 2025 [5] Group 4 - A total of 33 share repurchase plans have been disclosed on the Sci-Tech Innovation Board in 2025, with a maximum repurchase amount of 3.215 billion yuan [6] - Companies like Daotong Technology and Zhongwulian have announced share repurchase plans, reflecting confidence in their development [6] - Key figures in the integrated circuit and new energy sectors are actively increasing their shareholdings, indicating a commitment to the future value of their companies [6]

Core Viewpoint - Company Noratai Bio is expanding into the Middle East and Africa markets through a strategic partnership with Gulf Pharmaceutical Industries (Julphar), aiming to supply the active pharmaceutical ingredient semaglutide in 22 countries, which is expected to significantly increase its revenue and market presence [1][4][5]. Group 1: Strategic Partnership - Noratai Bio has announced a ten-year strategic cooperation with Julphar to supply semaglutide raw materials in the UAE, Qatar, Saudi Arabia, Egypt, Morocco, and other countries [4]. - The partnership includes providing necessary documentation for quality research and registration, as well as on-site technical support to address any production issues [4]. - Julphar, established in 1980, is one of the largest pharmaceutical companies in the Middle East and Africa, with a workforce of 3,400 and operations in over 30 countries [4]. Group 2: Revenue Growth - In the first half of 2024, Noratai Bio's overseas revenue accounted for approximately 56.38%, amounting to about 469 million yuan [6][7]. - The company has seen a significant increase in international sales, growing from just 0.14% in 2015 to over half of its revenue in 2024 [7]. - Noratai Bio's first-quarter net profit is expected to increase by 96% to 156% year-on-year, driven by the popularity of semaglutide and the expansion of its customer base [8]. Group 3: Market Expansion - The strategic move into the Middle East and Africa is seen as a milestone for Noratai Bio, enhancing its global commercialization capabilities and recognizing its strength in the GLP-1 field [5]. - The company has established collaborations in various international markets, including Europe, North America, and South America, indicating a robust global strategy [7]. - Noratai Bio's sales of peptide raw materials have reached markets such as the US, Europe, and India, with notable clients including Krka, Cipla, and Teva [7].

每经记者 许立波 每经编辑 董兴生 丨 2025年4月10日 星期四 丨 NO.1 新华医疗：医用电子直线加速器获得三类医疗器械注册证 4月9日，新华医疗发布公告称，公司于近日收到国家药品监督管理局颁发的《医疗器械注册证》，该产 品为"医用电子直线加速器"，适用范围为"用于对适合接受放射治疗的肿瘤病灶进行放射治疗、图像引 导放射治疗和体部立体定向放射治疗，具体适应症应由临床医生根据实际情况确定"。根据国家药品监 督管理局官网数据查询信息，截至目前，国内同行业有7家公司已取得同类产品的医疗器械注册证。 点评：该医用电子直线加速器的上市丰富了新华医疗放射治疗产品线，有利于提升公司的核心竞争力， 但行业内已有多家企业取得同类资质，市场竞争激烈，其后续商业化推广仍存挑战。 NO.2 诺泰生物：与中东药企Julphar达成战略合作 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自 担。 4月9日，诺泰生物公告称，公司与中东知名药企Gulf Pharmaceutical Industries(Julphar PSC)达成战略合 作，将在阿联酋、卡塔尔、沙特阿拉伯、埃及、摩洛哥等中东和非洲地 ...

特朗普称美国将对药品进口征收关税 当地时间4月8日，美国总统特朗普表示，美国将很快宣布对药品进口征收"重大"关税。据报道，特朗普 在全国共和党国会委员会的活动中发表讲话时表示，关税将刺激制药公司将其业务转移到美国。 药械审批 艾威药业眼科新药获FDA授予孤儿药资格 4月8日，艾威药业（IVIEW Therapeutics）宣布美国FDA已授予其研发的IVIEW-1201（1.0%聚维酮碘眼 用凝胶无菌溶液）孤儿药资格，用于治疗真菌性角膜炎（Fungal Keratitis, FK）。 这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 4月9日，诺泰生物公告，与中东知名药企Julphar PSC达成战略合作，将在阿联酋、卡塔尔、沙特阿拉 伯、埃及、摩洛哥等中东和非洲地区22个国家就司美格鲁肽原料药供应与Julphar达成相关约定。 21点评：此次合作覆盖阿联酋、卡塔尔、沙特阿拉伯等22个国家，聚焦司美格鲁肽原料药供应。诺泰生 物将借助Julphar在中东和非洲地区的商业化销售实力，进军中东和非洲地区这一潜力市场。这不仅标志 着诺泰生物在GLP-1领域的实力获 ...

| 证券代码：688076 | 证券简称：诺泰生物 | 公告编号：2025-021 | | --- | --- | --- | | 转债代码：118046 | 转债简称：诺泰转债 | | 江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露达成战略合作的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"或"诺泰 生物"）与中东知名药企 Gulf Pharmaceutical Industries (Julphar PSC) (以 下简称"Julphar")宣布达成战略合作，公司将在阿联酋、卡塔尔、沙特阿拉伯、 埃及、摩洛哥等中东和非洲地区 22 个国家就司美格鲁肽原料药供应与 Julphar 达成相关约定。 一、战略合作方的基本情况 （一）对方企业名称：Gulf Pharmaceutical Industries (Julphar PSC) （二）基本情况介绍： Julphar 成立于 1980 年，致力于向全球家庭提供高 质量、创新的平价药品，是中东和非洲地区最大的制 ...